Skip to content
Menu

Windward Bio Group AG WWB

Full chart Compare
Set alert

Price alert · WWB

All alert types
24.48 USD -5.56 (-18.51%)

As ofNov 17, 2026, 2:08 PM EST

21.38 Day range 29.67
18.35 52-week range 33.99
YTD
-14.11%
1 year
-14.11%
Market cap
1.41B
EPS (ttm)
-0.83
Shares out
58.04M
YTD return
-14.11%
1-year return
-14.11%
50-day average
28.50
Volume
176.79K
Avg volume
758.35K
Open
29.67
Previous close
30.04
Day's range
21.38 – 29.67
52-week range
18.35 – 33.99

5D +7.84 (+46.12%)

202530FriMonTue24.84

Key statistics

200-day average
28.50
Enterprise value
1.47B
Price / book
1.76
Total cash
186.47M
Total debt
474.00K

Fundamental scorecard

3 of 25 checks passed on WWB’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth No data
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Financials — quick view

All financials
WWB Revenue — annual 0
WWB Net income — annual -48.32M
WWB EPS — annual -7.44

About Windward Bio Group AG

Windward Bio Group AG operates as a clinical stage biotechnology company that develops ultra-long-acting antibody medicines for patients with respiratory and dermatologic diseases. Its drug candidates WIN378, an ultra-long-acting and novel fully human monoclonal antibody, which has completed Phase I clinical study that inhibits thymic stromal lymphopoietin (TSLP); and WIN027, an ultra-long-acting bispecific antibody that is in Phase I clinical study simultaneously targets TSLP and interleukin-13 (IL-13) and two clinically validated drivers of inflammatory disease. The company has collaboration agreements with Sichuan Kelun-Biotech BioPharmaceutical Co., Ltd, Harbour BioMed (Shanghai) Co., Ltd, and Qyuns Therapeutics Co., Ltd. Windward Bio Group AG was incorporated in 2024 and is based in Basel, Switzerland.

Sector
Healthcare
Industry
Biotechnology
Country
Switzerland

News

Your note

Sign in to keep a note on WWB — it syncs with the Stock Master app.